341 Intravenous iron support vs oral liposomal iron support in patients with refractory anemia treated with Epo alpha. Monocentric prospective study

MDS patients, with an overall erythroid response of 22.6%. The mechanism leading to haematological improvement, which seems to be dependent on serum ferritin reductions, remains to be elucidated. Factors that may play a role in this improvement include: reduction in iron overload with concomitant reduction in oxidative stress, specific pharmacological effect of the drug on haematopoiesis such as the ability to inhibit nuclear factor uB, or both. These analyses support previous observations reporting the ability of deferasirox to improve haematologic parameters in transfusion-dependent patients with MDS.